Determination of galectin-3 expression in the tissue of follicular thyroid tumors

Cover Page


The aim of this study was to investigate the usefulness of immunohistochemical expression galectin-3 for differential diagnosis follicular carcinoma and follicular adenoma in a sample of thyroid lesions using a specific antigalectin-3 monoclonal antibody. We evaluated 36 thyroid lesions including 15 follicular carcinomas, 15 follicular adenomas, and in 6 cases there was a combination of follicular carcinomas and follicular adenomas. Galectin-3 expression was detected in 8 of 15 (53.3%) follicular adenomas, 13 of 15 (86.7%) follicular carcinomas and in 6 of6 (100%) combined cases. The sensitivity, specificity, efficiency and diagnostic accuracy of this test method were73.6%, 81.8%, 77.7% and 77%, respectively. Galectin-3 expression determined in 53.3% of adenomas. The average level of the expression in adenoma cells was significantly lower compared with carcinoma. Galectin-3 can’t be used for differential immunohistochemical diagnosis of follicular thyroid tumors because the expression of the marker in cells of follicular carcinoma was only 86.7%. Expression of galectin-3 in the cells of adenomas with a combination of follicular adenoma and follicular cancer was revealed in all cases. In the adenoma tissue mean expression level was significantly lower than in carcinoma. So galectin-3 can’t be used as the sole marker but definition of the expression galectin-3 may be important in the complex diagnosis follicular thyroid tumors and also in combination with other markers. The expression of galectin-3 chance of having a malignant nature of the tumor was significantly higher.

About the authors


  1. Антонова С.С., Юшков П.В. Галектин-3 как представитель семейства лектинов: роль в норме и патологии // Молекулярная медицина. 2004. №1. С. 60–64.
  2. Абесадзе И.А. Дифференциальная диагностика фолликулярных опухолей щитовидной железы: Дис. … канд. мед. наук. М., 2008.
  3. Двинских Н.Ю. Морфологическая и иммуногистохимическая оценка злокачественности опухолей щитовидной железы: Дис. … канд. мед. наук. М., 2010.
  4. Краевский Н.А., Смольянников А.В., Саркисова Д.С. Патологоанатомическая диагностика опухолей человека: Руководство для врачей. М.: Медицина, 1993. С. 349–362.
  5. Пальцев М.А., Коган Е.А., Тунцова О.И. Иммуногистохимия биомолекулярных маркеров раннего рака щитовидной железы // Арх. патол. 1997. №6. С. 18–23.
  6. Трошина Е.А., Платонова Н.М., Юшков П.В., Солдатова Т.В. Заболевания щитовидной железы. Ультразвуковая и морфологическая диагностика / Под общ. ред. Мельниченко Г.А. М.: РКИ Северо-пресс, 2008. С. 55–58.
  7. Bartolazzi A., Gasbarri A. et al. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preop- erative diagno-sis of nodular thyroid lesions // Lancet. 2001. N357. P. 1644–1650.
  8. Bartolazzi A., Orlandi F. et al.Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study |// Lancet On-col. 2008. V. 9. N6. P. 508–510.
  9. Beesley M.F., McLaren K.M. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules // Histopathol. 2002. V. 41. N3. P. 236–243.
  10. Gasbarri A., Martegani M.P. et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules // J. Clin. Oncol. 1999. V. 17. N11. P. 3494–3502.
  11. Martins L., Маtsuo S.E. et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors // J. Clin. Endocrinol. Metab. 2002. V. 87. N10. P. 4806–4810.
  12. Saggiorato E., Aversa S. et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas // J. Endocrinol. Invest. 2004. V. 27. N24. P. 311–317.
  13. Delellis R.A., Lyoid R.V., Heitz P.U. World Health Organization Classification of Tumors. Pathology & Genetics. Lyon: IARC Press, 2004.



Abstract - 1110

PDF (Russian) - 723




Copyright (c) 2011 ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies